P006: Clinical outcome of classical Hodgkin Lymphoma patients receiving systemic anti-lymphoma treatment during SARS-COV-2 positivity: Results from the chemo-covid study on behalf of fondazione italiana linfomi

• Chiara Rusconi,
• Benedetta Puccini,
• Carlo Visco,
• Francesca Ricci,
• Alessandro Re,
• Vittorio R. Zilioli,
• Caterina Zerbi,
• Stefan Hohaus,
• Federico Mazzon,
• Manuel Ciceri,
• Anna Guidetti,
• Vincenzo Marasco,
• Luigi Rigacci

Affiliations

Chiara Rusconi

1 Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy

Benedetta Puccini

2 SOD Hematology, AOU Careggi, Firenze, Italy

Carlo Visco

3 Department of Medicine, Section of Hematology, University of Verona, Verona, Italy

Francesca Ricci

4 Department of Oncology and Hematology, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy

Alessandro Re

5 Hematology, ASST Spedali Civili di Brescia, Brescia, Italy

Vittorio R. Zilioli

6 Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy

Caterina Zerbi

7 Department of Molecular Medicine, University of Pavia and Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

Stefan Hohaus

8 Hematology, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy

Federico Mazzon

9 University of Milan, Milano, Italy

Manuel Ciceri

2 SOD Hematology, AOU Careggi, Firenze, Italy

Anna Guidetti

1 Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy

Vincenzo Marasco

1 Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy

Luigi Rigacci

10 UOC Hematology and Stem Cell Transplantation, AO San Camillo Forlanini, Roma, Italy